Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

Anti-CD19 Antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (3) Apoptosis (1) CD19 (17) CD3 (1) CD47 (1) IFNAR (2) Interleukin Related (2) TNF Receptor (1)
By Research Areas:	Cancer (8) Inflammation/Immunology (9)

Inhibitors & Agonists

Inhibitory Antibodies

Targets Recommended: ADC Antibody Antibody-Drug Conjugates (ADCs) Antibody-Oligonucleotide Conjugates (AOCs) ADC Linker PROTAC-Linker Conjugates for PAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P991028

Surovatamig AZD0486; TNB-486	CD3 CD19 Interleukin Related TNF Receptor IFNAR	Cancer
Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma .

HY-P99113

Inebilizumab 1 Publications Verification MEDI-551	ADC Antibody CD19	Inflammation/Immunology
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research .

HY-P99761

Obexelimab XmAb5871	CD19 Apoptosis	Inflammation/Immunology
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .

HY-P99113A

Inebilizumab (FUT8-KO)	CD19	Inflammation/Immunology
Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.Inebilizumab (FUT8-KO) exhibits enhanced ADCC against B cells and can be used for research on multiple sclerosis and neuromyelitis optica .

HY-P99285

Denintuzumab 1 Publications Verification hBU 12	ADC Antibody CD19	Cancer
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia .

HY-P99711

Loncastuximab RB4v1.2	CD19 ADC Antibody	Cancer
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab has antitumor activity and can be used in the research of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Loncastuximab is capable of synthesizing the ADC molecule Loncastuximab tesirine (HY-P99349) .

HY-P990870

Anti-CD19 Antibody (4G7)	CD19 IFNAR Interleukin Related	Inflammation/Immunology
Anti-CD19 Antibody (4G7) is an anti-human *CD19* IgG1 monoclonal antibody. Anti-CD19 Antibody (4G7) reduces the killing effect of CAR T cells on Raji cells. Anti-CD19 Antibody (4G7) can be used for research on immunology. Anti-CD19 Antibody (4G7) is often used in flow cytometry. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977) .

HY-P990349

**Anti-CD19 Antibody**	CD19	Inflammation/Immunology
The Anti-CD19 Antibody is a humanized antibody expressed in CHO cells, targeting *CD19. The Anti-CD19* Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD19 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990729

Budoprutug VB-119	CD19	Inflammation/Immunology
Budoprutug is an anti-CD19 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990694

Zeripatamig TG-1801	CD19 CD47	Inflammation/Immunology
Zeripatamig is an anti-CD19/CD47 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P99577

Taplitumomab	CD19	Cancer
Taplitumomab is an anti-CD19 monoclonal antibody. Taplitumomab paptox can be used in cancer research.

HY-P991839

Anti-CD19 Antibody (FMC63)	CD19	Cancer
Anti-CD19 Antibody (FMC63) is an anti-human CD19 antibody. Anti-CD19 Antibody (FMC63)recognizes an epitope in CD19 that is located between exons 2 and 4. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991542

GBR-401	CD19	Cancer
GBR-401 is a humanized anti-CD19 monoclonal antibody with high affinity for FcγRIIIa. GBR-401 exerts a potent in vitro and in vivo cytotoxic activity against various B-cell malignancies. GBR-401 induces cell death by antibody dependent cellular cytotoxicity (ADCC) and direct killing effect. GBR-401 demonstrates potent activity of depleting malignant B cells and prolongs mice survival in multiple xenograft severe combined immunodeficiency (SCID) mice models .

HY-P991897

Anti-CD19 Antibody (hA19)	CD19	Cancer
Anti-CD19 Antibody (hA19) is an antibody against human *CD19*. Recommend Isotype Controls:?Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991231

DI-B4	CD19	Cancer
DI-B4 is an anti-CD19 monoclonal antibody that can bind to *CD19* on the surface of B cells and has anti-tumor activity .

HY-P991900

LY3541860	CD19	Inflammation/Immunology
LY3541860 is a selective anti-CD19 antibody that both binds human CD19 with high affinity and selectively binds human B cells (K_d values: 76.8 pM and 94.5 nM for humans and cynomolgus monkeys, respectively). LY3541860 inhibits CpG-induced CD69 expression (IC₅₀ = 0.006 nM). LY3541860 exhibits potent B cell inhibitory activities. LY3541860 can inhibit both BCR- and TLR-induced human B cell activation. LY3541860 can be used for the research of autoimmune diseases .

HY-P991898

IASO-782 RD126	CD19	Inflammation/Immunology
IASO-782 (RD126) is a fully human monoclonal antibody targeting human *CD19. The Fc segment of IASO-782 is mutated to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) while maintaining the integrity of other Fc segment functions, such as ADCP. IASO-782 effectively eliminates CD19+ B cells, plasmablasts, and some plasma cells, thereby reducing or completely eliminating autoreactive antibodies* produced by these cells. IASO-782 can be used for the study of immune thrombocytopenic purpura (ITP), warm autoimmune hemolytic anemia (wAIHA) and systemic lupus erythematosus (SLE).

Cat. No.	Product Name	Target	Research Area	Image

HY-P991028

Surovatamig AZD0486; TNB-486	CD3 CD19 Interleukin Related TNF Receptor IFNAR	Cancer
Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma .

HY-P99113

Inebilizumab 1 Publications Verification MEDI-551	ADC Antibody CD19	Inflammation/Immunology
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research .

HY-P99761

Obexelimab XmAb5871	CD19 Apoptosis	Inflammation/Immunology
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .

HY-P99113A

Inebilizumab (FUT8-KO)	CD19	Inflammation/Immunology
Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.Inebilizumab (FUT8-KO) exhibits enhanced ADCC against B cells and can be used for research on multiple sclerosis and neuromyelitis optica .

HY-P99285

Denintuzumab 1 Publications Verification hBU 12	ADC Antibody CD19	Cancer
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia .

HY-P99711

Loncastuximab RB4v1.2	CD19 ADC Antibody	Cancer
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab has antitumor activity and can be used in the research of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Loncastuximab is capable of synthesizing the ADC molecule Loncastuximab tesirine (HY-P99349) .

HY-P990870

Anti-CD19 Antibody (4G7)	CD19 IFNAR Interleukin Related	Inflammation/Immunology
Anti-CD19 Antibody (4G7) is an anti-human *CD19* IgG1 monoclonal antibody. Anti-CD19 Antibody (4G7) reduces the killing effect of CAR T cells on Raji cells. Anti-CD19 Antibody (4G7) can be used for research on immunology. Anti-CD19 Antibody (4G7) is often used in flow cytometry. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977) .

HY-P990349

**Anti-CD19 Antibody**	CD19	Inflammation/Immunology
The Anti-CD19 Antibody is a humanized antibody expressed in CHO cells, targeting *CD19. The Anti-CD19* Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD19 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990729

Budoprutug VB-119	CD19	Inflammation/Immunology
Budoprutug is an anti-CD19 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990694

Zeripatamig TG-1801	CD19 CD47	Inflammation/Immunology
Zeripatamig is an anti-CD19/CD47 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P99577

Taplitumomab	CD19	Cancer
Taplitumomab is an anti-CD19 monoclonal antibody. Taplitumomab paptox can be used in cancer research.

HY-P991839

Anti-CD19 Antibody (FMC63)	CD19	Cancer
Anti-CD19 Antibody (FMC63) is an anti-human CD19 antibody. Anti-CD19 Antibody (FMC63)recognizes an epitope in CD19 that is located between exons 2 and 4. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991542

GBR-401	CD19	Cancer
GBR-401 is a humanized anti-CD19 monoclonal antibody with high affinity for FcγRIIIa. GBR-401 exerts a potent in vitro and in vivo cytotoxic activity against various B-cell malignancies. GBR-401 induces cell death by antibody dependent cellular cytotoxicity (ADCC) and direct killing effect. GBR-401 demonstrates potent activity of depleting malignant B cells and prolongs mice survival in multiple xenograft severe combined immunodeficiency (SCID) mice models .

HY-P991897

Anti-CD19 Antibody (hA19)	CD19	Cancer
Anti-CD19 Antibody (hA19) is an antibody against human *CD19*. Recommend Isotype Controls:?Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991231

DI-B4	CD19	Cancer
DI-B4 is an anti-CD19 monoclonal antibody that can bind to *CD19* on the surface of B cells and has anti-tumor activity .

HY-P991900

LY3541860	CD19	Inflammation/Immunology
LY3541860 is a selective anti-CD19 antibody that both binds human CD19 with high affinity and selectively binds human B cells (K_d values: 76.8 pM and 94.5 nM for humans and cynomolgus monkeys, respectively). LY3541860 inhibits CpG-induced CD69 expression (IC₅₀ = 0.006 nM). LY3541860 exhibits potent B cell inhibitory activities. LY3541860 can inhibit both BCR- and TLR-induced human B cell activation. LY3541860 can be used for the research of autoimmune diseases .

HY-P991898

IASO-782 RD126	CD19	Inflammation/Immunology
IASO-782 (RD126) is a fully human monoclonal antibody targeting human *CD19. The Fc segment of IASO-782 is mutated to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) while maintaining the integrity of other Fc segment functions, such as ADCP. IASO-782 effectively eliminates CD19+ B cells, plasmablasts, and some plasma cells, thereby reducing or completely eliminating autoreactive antibodies* produced by these cells. IASO-782 can be used for the study of immune thrombocytopenic purpura (ITP), warm autoimmune hemolytic anemia (wAIHA) and systemic lupus erythematosus (SLE).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: